Literature DB >> 1737399

Inverse relationship between trk expression and N-myc amplification in human neuroblastomas.

A Nakagawara1, M Arima, C G Azar, N J Scavarda, G M Brodeur.   

Abstract

We examined the expression of the trk protooncogene in a series of 82 neuroblastomas to determine its relationship to N-myc amplification and expression, disease stage, patient age, and survival. We found that virtually all stage I, II, and IV-S patients had moderate to high levels of trk expression, whereas most advanced stage neuroblastomas had low or absent levels. All but one tumor with N-myc amplification had low or absent trk expression, and the one exception was regressing at the time it was resected. Conversely, all neuroblastomas identified by mass screening had moderate to high expression of trk, and all these patients are surviving. Thus, trk expression was associated with an absence of N-myc amplification, lower disease stage, lower patient age, and favorable outcome. Tumors with high trk expression may be more likely to differentiate, regress spontaneously, or respond well to therapy.

Entities:  

Mesh:

Year:  1992        PMID: 1737399

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  51 in total

1.  TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.

Authors:  Jamie L Croucher; Radhika Iyer; Nanxin Li; Valentina Molteni; Jon Loren; W Perry Gordon; Tove Tuntland; Bo Liu; Garrett M Brodeur
Journal:  Cancer Chemother Pharmacol       Date:  2014-11-14       Impact factor: 3.333

2.  Integrative epigenomic and genomic analysis of malignant pheochromocytoma.

Authors:  Johanna Sandgren; Robin Andersson; Alvaro Rada-Iglesias; Stefan Enroth; Goran Akerstrom; Jan P Dumanski; Jan Komorowski; Gunnar Westin; Claes Wadelius
Journal:  Exp Mol Med       Date:  2010-07-31       Impact factor: 8.718

3.  AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts.

Authors:  Radhika Iyer; Carly R Varela; Jane E Minturn; Ruth Ho; Anisha M Simpson; Jennifer E Light; Audrey E Evans; Huaqing Zhao; Kenneth Thress; Jeffrey L Brown; Garrett M Brodeur
Journal:  Cancer Chemother Pharmacol       Date:  2012-05-24       Impact factor: 3.333

Review 4.  Therapeutic targets for neuroblastomas.

Authors:  Garrett M Brodeur; Radhika Iyer; Jamie L Croucher; Tiangang Zhuang; Mayumi Higashi; Venkatadri Kolla
Journal:  Expert Opin Ther Targets       Date:  2014-01-06       Impact factor: 6.902

5.  Expression of TrkA, TrkB and TrkC in human neuroblastomas.

Authors:  G M Brodeur; A Nakagawara; D J Yamashiro; N Ikegaki; X G Liu; C G Azar; C P Lee; A E Evans
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

6.  N-myc amplification and its relationship to experimental therapy.

Authors:  A Livingstone; R J Mairs
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

Review 7.  Spontaneous regression of neuroblastoma.

Authors:  Garrett M Brodeur
Journal:  Cell Tissue Res       Date:  2018-01-05       Impact factor: 5.249

Review 8.  Mechanisms of neuroblastoma regression.

Authors:  Garrett M Brodeur; Rochelle Bagatell
Journal:  Nat Rev Clin Oncol       Date:  2014-10-21       Impact factor: 66.675

Review 9.  Neuroblastoma.

Authors:  Andrew M Davidoff
Journal:  Semin Pediatr Surg       Date:  2012-02       Impact factor: 2.754

10.  Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification.

Authors:  Loen M Hansford; Wayne D Thomas; Joanna M Keating; Catherine A Burkhart; Anne E Peaston; Murray D Norris; Michelle Haber; Patricia J Armati; William A Weiss; Glenn M Marshall
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.